Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to F/TAF in Virologically Suppressed HIV-1 Patients
NCT02121795Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- May 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started May 2014; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02121795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121795.